VERAPAMIL
-
| StockNo |
Product description |
| EB0280-424-25 |
VERAPAMIL
AMPOULE 5 MG/2 ML |
| EB0280-42-440 |
VERAPAMIL
FILMTABL 80 MG X 30 |
-
- COMPOSITION:
Verapamil hydrochloride 5 mg/2 ml injection solution,
80 mg in one filmtablet.
ACTION:
The drug belongs to the group of calcium antagonists. The mechanism
of its action is associated with blocking of calcium ions influx
through the slow calcium channels in cellular membranes. It
suppresses the activity of the sinus node and slows down AV
conduction predominantly. It has a local anesthetic activity similar
to that of procain. It induces peripheral and coronary vasodilatory
effect as a result of the inhibitory action on the smooth muscles of
the vessels. The drug has a negative chrono-, dromo- and inotropic
effect. It reduces the oxygen demand of the myocardium.
PHARMACOKINETICS:
Verapamil is well absorbed in the digestive tract and is subjected
to biotransformation in the liver into less active metabolites.
About 90 % of the drug binds to blood plasma proteins. With oral
administration the effect is attained after 1/2-2 h and lasts for 6
h. its plasma half-life is 3-4 hours.
INDICATIONS:
Supraventicular arrythmia (paroxysmal tachycardia, arterial
extrasystoles and paroxysmal arrhythmia); angina pectoris, light and
moderately grave hypertension, in combination with other hypotensive
agents and in hypertrophic cardiomyopathies.
CONTRAINDICATIONS:
Cardiogenic shock, acute myocardial infarction complicated with
bradycardia, hypotension, left-venticular insufficiency,
AV-syndrome); uncompensated cardiac insufficiency; marked
bradycardia and arterial hypotension; pronounced cardiac
insufficiency, as well as during the first three months of
pregnancy.
SIDE EFFECTS:
Dizziness, nausea, and in high doses - hypotension, disturbances in
consciousness are likely to be observed, as well as sinus
bardycardia that can develop into asystole and AV-block. |
